HUMA
Humacyte, Inc. NASDAQ Listed Dec 1, 2020$1.08
Mkt Cap $169.3M
52w Low $0.55
22.4% of range
52w High $2.93
50d MA $0.87
200d MA $1.32
P/E (TTM)
-3.3x
EV/EBITDA
-1.7x
P/B
43.4x
Debt/Equity
20.9x
ROE
-1313.4%
P/FCF
-1.4x
RSI (14)
—
ATR (14)
—
Beta
2.10
50d MA
$0.87
200d MA
$1.32
Avg Volume
6.8M
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
2525 East North Carolina Highway 54 · Durham, NC 27713 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.13 | -0.13 | +0.0% | 0.68 | +3.4% | -15.0% | +5.6% | -2.4% | +8.5% | +1.2% | — |
| Nov 12, 2025 | AMC | -0.17 | -0.14 | +17.6% | 1.25 | -1.6% | -4.8% | +3.4% | -8.1% | +6.2% | -2.5% | — |
| Aug 11, 2025 | AMC | -0.15 | -0.24 | -60.0% | 1.75 | +4.0% | +2.9% | -1.1% | +5.6% | +0.0% | -4.3% | — |
| May 13, 2025 | AMC | -0.19 | -0.10 | +47.4% | 1.73 | +2.3% | +8.1% | +1.1% | +18.5% | -0.4% | +11.7% | — |
| Mar 28, 2025 | AMC | -0.23 | -0.16 | +30.4% | 1.96 | -3.1% | -12.8% | -12.9% | -2.0% | -0.7% | -6.9% | — |
| Nov 8, 2024 | AMC | -0.26 | -0.33 | -26.9% | 5.78 | +0.3% | -4.5% | -2.9% | -0.4% | -9.4% | +0.0% | — |
| Aug 13, 2024 | AMC | -0.23 | -0.27 | -17.4% | 6.65 | +0.0% | -9.6% | +2.2% | +5.5% | -2.3% | -1.3% | — |
| May 10, 2024 | AMC | -0.23 | -0.29 | -26.1% | 4.70 | +0.9% | +16.6% | +17.2% | +0.8% | -0.8% | -1.4% | — |
| Mar 22, 2024 | AMC | -0.25 | -0.24 | +4.0% | 3.31 | +0.3% | -5.1% | -2.2% | +1.0% | +0.3% | -3.2% | — |
| Nov 9, 2023 | AMC | -0.25 | -0.25 | +0.0% | 2.21 | +2.3% | +6.3% | -4.3% | +6.2% | +4.6% | -2.4% | — |
| Aug 14, 2023 | AMC | -0.22 | -0.22 | +0.0% | 4.04 | -3.5% | +10.9% | -6.5% | -15.5% | +0.6% | -5.3% | — |
| May 12, 2023 | AMC | -0.22 | -0.22 | +0.0% | 3.97 | +1.3% | +0.4% | -2.4% | +6.4% | +1.7% | -1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | BTIG | Maintains | Buy → Buy | — | $0.81 | $0.82 | +2.4% | +5.2% | -3.2% | +2.7% | +1.6% | +8.1% |
| Apr 28 | D. Boral Capital | Maintains | Buy → Buy | — | $0.81 | $0.82 | +2.4% | +5.2% | -3.2% | +2.7% | +1.6% | +8.1% |
| Apr 24 | D. Boral Capital | Maintains | Buy → Buy | — | $0.71 | $0.71 | +0.0% | -1.1% | +15.1% | +5.2% | -3.2% | +2.7% |
| Apr 21 | D. Boral Capital | Maintains | Buy → Buy | — | $0.69 | $0.69 | -0.3% | -4.1% | +7.0% | +0.5% | -1.1% | +15.1% |
| Apr 8 | Barclays | Maintains | Overweight → Overweight | — | $0.61 | $0.65 | +7.1% | +7.3% | -6.8% | +6.3% | +3.8% | +3.1% |
| Mar 31 | Benchmark | Maintains | Buy → Speculative Buy | — | $0.57 | $0.59 | +2.5% | +5.6% | -2.4% | +8.5% | +1.2% | -6.6% |
| Mar 30 | TD Cowen | Maintains | Buy → Buy | — | $0.68 | $0.70 | +3.4% | -15.0% | +5.6% | -2.4% | +8.5% | +1.2% |
| Mar 30 | Piper Sandler | Maintains | Neutral → Neutral | — | $0.68 | $0.70 | +3.4% | -15.0% | +5.6% | -2.4% | +8.5% | +1.2% |
| Mar 27 | D. Boral Capital | Maintains | Buy → Buy | — | $0.78 | $0.74 | -4.9% | -13.2% | -15.0% | +5.6% | -2.4% | +8.5% |
| Mar 27 | BTIG | Maintains | Buy → Buy | — | $0.78 | $0.74 | -4.9% | -13.2% | -15.0% | +5.6% | -2.4% | +8.5% |
| Mar 19 | D. Boral Capital | Maintains | Buy → Buy | — | $1.06 | $0.98 | -7.9% | -19.4% | -8.3% | +8.6% | -6.6% | +3.6% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $1.12 | $1.12 | +0.0% | +3.6% | -8.6% | -19.4% | -8.3% | +8.6% |
| Feb 19 | D. Boral Capital | Maintains | Buy → Buy | — | $1.08 | $1.09 | +0.9% | +6.5% | -1.7% | +0.9% | -1.8% | +3.6% |
| Feb 9 | D. Boral Capital | Maintains | Buy → Buy | — | $0.94 | $1.02 | +8.7% | +30.0% | -13.9% | -3.8% | +0.0% | +0.0% |
| Feb 9 | BTIG | Maintains | Buy → Buy | — | $0.94 | $1.02 | +8.7% | +30.0% | -13.9% | -3.8% | +0.0% | +0.0% |
| Jan 21 | Benchmark | Maintains | Buy → Buy | — | $1.02 | $1.03 | +1.0% | -3.9% | +14.3% | -6.2% | -2.9% | +1.0% |
| Jan 8 | D. Boral Capital | Maintains | Buy → Buy | — | $1.20 | $1.20 | +0.0% | -2.5% | +0.0% | -3.4% | -1.8% | +2.7% |
| Jan 5 | D. Boral Capital | Maintains | Buy → Buy | — | $0.97 | $1.01 | +3.6% | +8.7% | +1.9% | +11.1% | -2.5% | +0.0% |
| Dec 22 | D. Boral Capital | Maintains | Buy → Buy | — | $1.11 | $1.13 | +1.8% | -3.6% | +5.6% | -4.4% | -0.9% | -4.7% |
| Nov 21 | BTIG | Maintains | Buy → Buy | — | $1.12 | $1.11 | -0.9% | +8.9% | +4.9% | +3.1% | +0.8% | +1.5% |
| Nov 20 | D. Boral Capital | Maintains | Buy → Buy | — | $1.17 | $1.19 | +1.7% | -4.3% | +8.9% | +4.9% | +3.1% | +0.8% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $1.25 | $1.23 | -1.6% | -4.8% | +3.4% | -8.1% | +6.2% | -2.5% |
| Nov 13 | Benchmark | Maintains | Buy → Buy | — | $1.25 | $1.23 | -1.6% | -4.8% | +3.4% | -8.1% | +6.2% | -2.5% |
| Nov 12 | D. Boral Capital | Maintains | Buy → Buy | — | $1.28 | $1.43 | +11.7% | -2.3% | -4.8% | +3.4% | -8.1% | +6.2% |
| Nov 10 | D. Boral Capital | Maintains | Buy → Buy | — | $1.33 | $1.39 | +4.5% | +1.5% | -5.2% | -2.3% | -4.8% | +3.4% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $1.56 | $1.60 | +2.6% | +12.8% | +1.7% | -1.1% | -4.0% | +1.2% |
| Oct 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.10 | $2.30 | +9.5% | +18.1% | -33.5% | +2.4% | -3.0% | -4.9% |
| Sep 30 | D. Boral Capital | Maintains | Buy → Buy | — | $1.73 | $1.73 | +0.0% | +0.6% | +1.1% | +1.7% | +17.3% | +18.1% |
| Sep 18 | D. Boral Capital | Maintains | Buy → Buy | — | $1.53 | $1.57 | +2.6% | +17.0% | +3.9% | -4.8% | -4.0% | -1.2% |
| Sep 15 | D. Boral Capital | Maintains | Buy → Buy | — | $1.47 | $1.50 | +2.0% | +4.1% | +2.6% | -2.5% | +17.0% | +3.9% |
| Aug 12 | TD Cowen | Maintains | Buy → Buy | — | $1.75 | $1.82 | +4.0% | +2.9% | -1.1% | +5.6% | +0.0% | -4.3% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.75 | $1.82 | +4.0% | +2.9% | -1.1% | +5.6% | +0.0% | -4.3% |
| Aug 11 | D. Boral Capital | Maintains | Buy → Buy | — | $2.48 | $2.04 | -17.7% | -29.4% | +2.9% | -1.1% | +5.6% | +0.0% |
| Jul 23 | D. Boral Capital | Maintains | Buy → Buy | — | $2.30 | $2.51 | +9.1% | +18.7% | -2.2% | -5.2% | -2.4% | -4.0% |
| Jul 9 | D. Boral Capital | Maintains | Buy → Buy | — | $2.57 | $2.62 | +1.9% | -1.2% | -1.2% | -8.0% | +6.9% | -7.7% |
| Jun 9 | D. Boral Capital | Maintains | Buy → Buy | — | $2.59 | $2.62 | +1.2% | -1.2% | +4.3% | -4.9% | -5.1% | -1.7% |
| May 14 | Benchmark | Maintains | Buy → Buy | — | $1.73 | $1.77 | +2.3% | +8.1% | +1.1% | +18.5% | -0.4% | +11.7% |
| May 13 | D. Boral Capital | Maintains | Buy → Buy | — | $1.32 | $1.57 | +18.9% | +31.1% | +8.1% | +1.1% | +18.5% | -0.4% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $1.96 | $1.90 | -3.1% | -12.8% | -12.9% | -2.0% | -0.7% | -6.9% |
| Mar 28 | D. Boral Capital | Maintains | Buy → Buy | — | $2.01 | $2.12 | +5.5% | -2.5% | -12.8% | -12.9% | -2.0% | -0.7% |
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $2.88 | $2.02 | -29.9% | -30.6% | +0.5% | -2.5% | -12.8% | -12.9% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.00 | $3.03 | +1.0% | -0.3% | -7.4% | +9.7% | -1.0% | +4.0% |
| Mar 7 | D. Boral Capital | Maintains | Buy → Buy | — | $2.96 | $2.97 | +0.3% | +4.4% | -6.1% | +3.4% | -0.3% | -7.4% |
| Feb 27 | Benchmark | Maintains | Buy → Buy | — | $3.43 | $3.59 | +4.7% | -1.7% | +0.9% | -10.0% | +4.6% | -1.6% |
| Feb 27 | D. Boral Capital | Maintains | Buy → Buy | — | $3.43 | $3.59 | +4.7% | -1.7% | +0.9% | -10.0% | +4.6% | -1.6% |
| Feb 26 | D. Boral Capital | Maintains | Buy → Buy | — | $3.04 | $3.32 | +9.2% | +12.8% | -1.7% | +0.9% | -10.0% | +4.6% |
| Jan 21 | D. Boral Capital | Maintains | Buy → Buy | — | $4.41 | $4.45 | +0.9% | +3.4% | +0.7% | +0.0% | +0.4% | -2.2% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $4.61 | $4.58 | -0.7% | -4.8% | -6.2% | +11.2% | -2.2% | -1.6% |
| Dec 23 | Benchmark | Maintains | Buy → Buy | — | $4.64 | $4.90 | +5.6% | +0.2% | -3.0% | +17.3% | +4.0% | -7.5% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.46 | $5.78 | +67.1% | +34.1% | +0.2% | -3.0% | +17.3% | +4.0% |
No insider trades available.
8-K
Humacyte, Inc. -- 8-K Filing
May 8
8-K · 1.01
!! High
Humacyte, Inc. -- 8-K 1.01: Material Agreement
Humacyte signed a material agreement with Fresenius Medical Care, potentially expanding its regenerative medicine vascular graft technology into Fresenius's extensive dialysis and renal care markets globally.
Apr 24
Data updated apr 25, 2026 2:22pm
· Source: massive.com